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A new treatment program has to prove its efficacy in a randomized controlled 
trial (RCT). However, healthcare research trials (HCRT) show that the effective-
ness of education programs is far less convincing in daily routine. We evaluated 
whether a new education and treatment program for type 1 diabetic patients 
(PRIMAS) had similar effects in daily routine as in the RCT. 255 people with type 
1 diabetes from 42 practices took part in the PRIMAS course and were observed 
in this HCRT. As in the RCT, PRIMAS consisted of 12 lessons and the outcomes 
were assessed 6 months after the education course. Primary outcome in both 
studies was HbA1c assessed in the same central laboratory. Improvement in 
hypoglycemia awareness, depressive symptoms, diabetes-related distress, self-
efficacy, and diabetes empowerment were secondary outcomes. In order to 
compare the effects of PRIMAS in the RCT with the effects in the HCRT, effect 
sizes of differences for each study were contrasted. The difference of the two 
respective effect sizes (RCT – HCRT) along with the 95% confidence interval was 
analyzed. HbA1c reduction in the RCT was -0.36% (-3.9 mmol/mol) as compared 
to -0.39% (-4.3 mmol/mol) in the HCRT. The difference of the effect sizes didn’t 
exceed the non-inferiority margin of 0.4 (difference of effect size: Δ -0.03, 95% 
CI -0.29 to 0.22). Effect sizes in all secondary outcomes were also highly com-
parable: Improvement of hypoglycemia awareness Δ 0.11, 95% CI -0.15 to 0.38; 
reduction of depressive symptoms Δ -0.08, 95% CI -0.34 to 0.18; reduction of 
diabetes distress Δ 0.23, 95% CI -0.04 to 0.49; improvement of self-efficacy Δ 
0.05, 95% CI -0.21 to 0.32; improvement of empowerment Δ 0.04, 95% CI -0.23 
to 0.36. PRIMAS proofed its effectiveness in daily routine and showed similar 
effect sizes as in the RCT. PRIMAS can contribute to an improvement of routine 
health care in people with type 1 diabetes.
Table 1:   Sample Characteristics
The efficacy of education and treatment programs for people with diabetes have 
been proven in many randomized controlled trials (RCT). However, to fully analyze 
the goodness of an education program, it has to be evaluated in daily routine and has 
to prove its effectiveness outside of an artificially controlled trial as well. Healthcare 
research trials (HCRT) evaluating the effectiveness of interventions often show that 
a effect in a RCT couldn’t withstand the challenges of clinical practice. In this study, 
we evaluated whether the RCT-proven efficacy of a new education and treatment 
program for people with type 1 diabetes (PRIMAS) could be replicated in a HCRT.
A B S T R A C T
I N T R O D U C T I O N
C O N C L U S I O N
R E S U L T S
M E T H O D S
PRIMAS is a structured education and treatment program for people with type 1 
diabetes consisting of 12 lessons. PRIMAS was evaluated in a RCT with a 6-month 
follow-up and demonstrated its efficacy by significantly improving glycemic control.
In the HCRT, practices conducted a PRIMAS course according to their clinical routine 
(no randomization, no control group). As in the RCT, patients completed a baseline 
measurement prior to the education and 6 months after the end of the education 
Primary Outcome:
• In the RCT, PRIMAS lead to reduction in HbA1c of -0.36 ± 1.0% (-3.9 mmol/mol). 
In the HCRT, HbA1c was significantly reduced by -0.39 ± 1.0% (-4.3 mmol/mol) 
(p < .05). 
• The difference between the two effects didn’t exceed the non-inferiority margin 
of 0.4 (difference of effect sizes: Δ -0.03, 95% CI -0.29 to 0.22; figure 1).
Secondary Outcome:
The effects of PRIMAS in the HCRT were similar to those achieved in the RCT (figure 
3). Thus, effect sizes in all secondary outcomes were highly comparable (figure 4):
• Reduction of hypoglycemia unawareness:
o  RCT: -0.5 vs. HCRT: -0.4
o  Effect size of difference: Δ 0.11, 95% CI -0.15 to 0.38
•  Reduction of depressive symptoms 
o  RCT: -1.2 vs. HCRT: -1.8
o  Effect size of difference: Δ -0.08, 95% CI -0.34 to 0.18
• Reduction of diabetes-related distress
o  RCT: -0.3 vs. HCRT: -0.2
o  Effect size of difference: Δ 0.23, 95% CI -0.04 to 0.49
• Improvement of self-efficacy
o  RCT: 1.4 vs. HCRT: 1.1
o  Effect size of difference: Δ 0.05, 95% CI -0.21 to 0.32
• Improvement of empowerment
o  RCT: 2.4 vs. HCRT: 2.3
o  Effect size of difference: Δ 0.04, 95% CI -0.23 to 0.36
Figure 4: Effect sizes of differences in primary and secondary outcomes (RCT - HCRT)
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Figure 1:  Reduction in HbA1c
course. Primary outcome in both studies was HbA1c assessed in the same central 
laboratory. Improvement in hypoglycemia unawareness (Clarke questionnaire), de-
pressive symptoms (CES-D), diabetes-related distress (DDS), self-efficacy (GSE), and 
diabetes empowerment (DES) were secondary outcomes. In order to compare the 
effects of PRIMAS in the RCT with the effects in the HCRT, effect sizes of differences 
in each outcome were analyzed. The difference (baseline – follow-up) of effects (RCT 
– HCRT) along with the 95% confidence interval was analyzed.
255 people with type 1 diabetes from 42 practices took part in the PRIMAS course 
and were observed in this HCRT. In the RCT, 75 patients were randomized to PRIMAS 
and completed the 6-month follow-up. Differences of both samples can be seen in 
table 1 and table 2.
Figure 2:  Difference of effect sizes regarding  
HbA1c reduction of the RCT and HCRT
This healthcare research trial demonstrated the effectiveness of PRIMAS. Under rou-
tine care conditions, PRIMAS was able to improve glycemic control in a 6-month 
follow-up. This effect was equivalent to the effect demonstrated in the RCT. Further-
more, the effects on secondary outcomes PRIMAS achieved in the RCT could be repli-
cated in the HCRT. PRIMAS proved to be a potent tool for clinical practice to educate 
patients with type 1 diabetes. Therefore, PRIMAS can contribute to an improvement 
of routine healthcare in people with type 1 diabetes.
Figure 3:  Comparison of improvements in secondary outcomes
